{
    "name": "insulin lispro protamine/insulin lispro",
    "comment": "Rx",
    "other_names": [
        "Humalog Mix 50/50",
        "Humalog Mix 50/50 Kwikpen",
        "Humalog Mix 75/25",
        "Humalog Mix 75/25 Kwikpen"
    ],
    "classes": [
        "Antidiabetics",
        "Insulins"
    ],
    "source": "https://reference.medscape.com/drug/humalog-mix-50-50-insulin-lispro-protamine-insulin-lispro-999553",
    "pregnancy": {
        "common": [
            "The limited available data in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes; published studies during pregnancy have not reported association between drug and induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes; there are risks to mother and fetus associated with poorly controlled diabetes in pregnancy",
            "Poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications; also increases fetal risk for major birth defects, still birth, and macrosomia related morbidity"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Pregnant rats and rabbits exposed to drug during organogenesis showed no adverse effects on embryo/fetal viability or morphology in offsprings administered a dose approximately 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day; no adverse effects on embryo/fetal development were observed in offspring of rabbits exposed to insulin lispro at doses up to approximately 0.24 times the human subcutaneous dose of 1 unit/kg/day"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production; one small published study reported exogenous insulin present in human milk; however, there is insufficient information to determine effects on breastfed infant and no available information on the effects on milk production; the developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for insulin, any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "During episodes of hypoglycemia"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Never share pen between patients even it needle is changed",
                "Suspension for SC use, do not administer IV",
                "Administer within 15 minutes of meals (rapid onset and peak ~1 hr)",
                "Rapid changes in serum glucose may induce symptoms of hypoglycemia",
                "Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions (eg, long duration of diabetes, diabetic nerve disease, use of beta-blockers or intensified diabetes control)",
                "Caution in conditions with decreased insulin requirements (eg, diarrhea, nausea, vomiting, malabsorption, hypothyroidism, renal impairment, hepatic impairment)",
                "Caution in conditions with increased insulin requirements (eg, fever, hyperthyroidism, trauma, infection, surgery)",
                "Do not administer via insulin infusion pump",
                "Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists and can cause dose-related fluid retention, particularly when used in combination with insulin; fluid retention may lead to or exacerbate heart failure, monitor for signs and symptoms of heart failure and treat accordingly and consider discontinuing thiazolidinediones",
                "Glucose monitoring recommended for all patients with diabetes",
                "Accidental mix-ups between this medication and other insulin products reported; to avoid medication errors between this medication and other insulins, instruct patients to always check insulin label before each injection",
                "Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including this medication; if hypersensitivity reactions occur, discontinue therapy; treat per standard of care and monitor until symptoms and signs resolve ",
                "Accidental mix-ups between insulin products can occur; instruct patients to check insulin labels before injection",
                "Severe, life-threatening, generalized allergy, including anaphylaxis, reported; discontinue therapy, monitor, and treat if indicated",
                "All insulin products cause a shift in potassium from extracellular to intracellular space, possibly leading to hypokalemia; untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death; monitor potassium levels in patients at risk for hypokalemia if indicated (eg, patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations)"
            ],
            "specific": [
                {
                    "type": "Hyperglycemia or hypoglycemia with changes in insulin regimen",
                    "description": [
                        "Changes in an insulin regimen (eg, insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia [or hyperglycemia",
                        "Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis reported to result in hyperglycemia, and sudden change in injection site (to an unaffected area) reported to result in hypoglycemia",
                        "Make any changes to patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring",
                        "Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change injection site to unaffected areas and closely monitor for hypoglycemia",
                        "For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed"
                    ]
                },
                {
                    "type": "Hypoglycemia",
                    "description": [
                        "Hypoglycemia is the most common adverse reaction associated with all insulin therapies; severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life-threatening, or cause death",
                        "Hypoglycemia can impair concentration ability and reaction time, this may place an individual and others at risk in situations where these abilities are important (eg, driving or operating other machinery)",
                        "Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual; symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system(eg, beta-blockers), or in patients who experience recurrent hypoglycemia.",
                        "The risk of hypoglycemia after injection is related to duration of action of insulin and in general, is highest when glucose-lowering effect of insulin is maximal; as with all insulin preparations, the glucose-lowering effect time course of this medication may vary in different individuals or at different times in same individual and depends on many conditions, including area of injection as well as injection site blood supply and temperature",
                        "Other factors which may increase risk of hypoglycemia include changes in meal pattern (eg, macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication",
                        "Patients with renal or hepatic impairment may be at higher risk of hypoglycemia",
                        "Patients and caregivers must be educated to recognize and manage hypoglycemia; self-monitoring of blood glucose plays essential role in prevention and management of hypoglycemia; in patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hypoglycemia",
            "percent": null
        },
        {
            "name": "Insulin resistance",
            "percent": null
        },
        {
            "name": "Lipodystrophy",
            "percent": null
        },
        {
            "name": "Lipohypertrophy",
            "percent": null
        },
        {
            "name": "Local allergic reaction",
            "percent": null
        },
        {
            "name": "Hypokalemia",
            "percent": null
        },
        {
            "name": "Injection site reactions",
            "percent": null
        },
        {
            "name": "Weight gain",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        }
    ]
}